S-1/A: Functional Brands Files S-1/A for Nasdaq Direct Listing

Functional Brands Inc. is pursuing a direct listing on Nasdaq, registering 17.88 million shares for resale, while facing recurring losses and a going concern doubt.

Summary

• Functional Brands Inc. (formerly HT Naturals Inc.) is seeking a direct listing on the Nasdaq Capital Market under the symbol MEHA, registering up to 17,883,693 shares of common stock for resale by existing stockholders.
• The company will not receive any proceeds from the sale of shares by Registered Stockholders in this direct listing.
• A private placement of Series A and Series B Convertible Preferred Stock, totaling $8,000,000 in funding, is conditioned upon the completion of the direct listing.
• The company operates in the nutraceutical supplement industry (Kirkman brand, P2i prenatal) and the hemp-derived products industry (HempTown Naturals, Golf Mellow).
• For the six months ended June 30, 2025, net revenue decreased by 2% to $3,422,789, resulting in an operating loss of $187,536 and a net loss of $352,838.
• For the year ended December 31, 2024, net revenue decreased by 4% to $6,566,455, with a net loss of $559,356.
• The company has a significant accumulated deficit of $8,013,768 as of June 30, 2025, and its auditors have expressed substantial doubt about its ability to continue as a going concern.
• A balance of $2,227,366 is owed for the Kirkman acquisition, due by November 15, 2025, with multiple forbearance agreements in place.
• The company is negotiating the termination of an exclusive license agreement with Trailer Park Boys Inc. for hemp-derived products, effective December 31, 2025, with up to $150,000 in remaining royalties due by March 31, 2026.
• Functional Brands is an emerging growth company and a smaller reporting company, electing to comply with reduced public company reporting requirements.

Sentiment

Score: 2

Explanation: The company faces significant financial distress, evidenced by recurring losses, negative cash flows, and an accumulated deficit, leading to a 'going concern' doubt from auditors. While there are growth strategies and a direct listing planned, the high-risk nature of the listing, substantial debt obligations, and reliance on a few key customers present considerable challenges. The repeated delays in acquisition payments and the need for future capital raises further underscore the precarious financial position.

Positives

• The Kirkman brand has a 70+ year history with a loyal consumer base and maintains high purity and quality standards, including rigorous testing of every product batch for heavy metals and microbial contamination.
• The P2i by Kirkman prenatal vitamin is the only certified prenatal vitamin in the market that aligns with the International Federation of Gynecology and Obstetrics (FIGO) position statement on low-toxicity standards.
• The company plans to strengthen its existing Kirkman brand, launch multiple new brands including P2i, modernize manufacturing capabilities, and invest in sales and marketing.
• The global nutritional supplements market is valued at approximately $405.15 billion in 2023 and is expected to grow at a CAGR of 6.3% through 2030, providing a favorable industry backdrop.
• The global CBD consumer health market was valued at $19.5 billion in 2023 and is anticipated to grow at a CAGR of 18.1%, indicating strong market potential for hemp-derived products.

Negatives

• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and a significant accumulated deficit.
• Net revenue decreased by 2% for the six months ended June 30, 2025, and by 4% for the year ended December 31, 2024, primarily due to lower demand from contract manufacturing customers.
• The company experienced a significant increase in net loss, from $6,475 in H1 2024 to $352,838 in H1 2025, representing a 5,549% decrease in profitability.
• Operating expenses increased by 17% for general and administrative costs and 15% for sales and marketing in H1 2025 compared to H1 2024.
• A significant payable for acquisition of $2,227,366 is due by November 15, 2025, with a confession of judgment allowing foreclosure on assets if not paid.
• The direct listing process is novel and may result in higher price and volume volatility compared to a firm-commitment underwritten IPO, with no predetermined initial public offering price.
• The company relies heavily on two customers, iHerb and OceanSide Health, which accounted for 55% of sales in H1 2025 and 54% in 2024, posing a significant risk if either relationship is lost.
• The company has a limited operating history, particularly in its hemp operations, and may not be able to successfully execute its business plan or manage future growth effectively.
• The company has incurred significant debt, including related-party loans, and will require additional financing in the future, which may be costly and dilutive to existing shareholders.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and a significant accumulated deficit.
• Inability to effectively manage future growth, leading to capacity constraints and pressure on internal systems and controls.
• Need for additional financing in the future, which may not be available when needed or may be costly and dilutive.
• Competition in brand-conscious industries (hemp and supplements) from larger, well-financed manufacturers and distributors, potentially affecting distribution relationships and market expansion.
• Inability to maintain a positive brand image due to negative public relations, product quality issues, or perceptions regarding the hemp industry.
• Rapid changes in consumer preferences and public perception in the industry, requiring continuous new product development to maintain long-term success.
• Inability to respond effectively to technological changes in the industry, which could reduce demand for products.
• Reduced demand for smokable products due to health concerns and legislative initiatives, including new taxes or regulations.
• Uncertain and evolving federal, state, and local regulations concerning hemp, CBD, CBG, and other non-tobacco consumable products, which could have a material adverse effect on the business.
• Potential for international expansion efforts to significantly increase operational expenses and regulatory risks.
• Reliance on distributors, retailers, and brokers, and the risk of losing key accounts or their inadequate performance.
• Potential for product liability claims, product recalls, or other product quality issues, which could damage reputation and financial results.
• Difficulty in predicting the timing and amount of sales, leading to uncertain sales forecasts and potential inventory management issues.
• Increases in costs or shortages of raw materials (including hemp) and energy, which could harm business and financial results.
• Disruption within the supply chain, contract manufacturing, or distribution channels due to various factors including natural disasters, pandemics, or labor strikes.
• Inability to attract and retain key personnel, including executive officers, which could impair efficiency and operations.
• Disruptions to information technology systems due to cyber-attacks or failure to upgrade systems, potentially impairing operations and growth.
• Fluctuations in quarterly results due to seasonality and other factors, making period-to-period comparisons unreliable.
• Adverse impacts from global economic, political, social, and other conditions, including geopolitical instability and economic uncertainty.
• Changes in accounting standards and subjective assumptions by management related to complex accounting matters, which could significantly affect financial results.
• Potential inability to satisfy Nasdaq listing requirements or maintain a listing, which could impair shareholders' ability to trade common stock.
• Volatility in the market price of common stock due to the novel direct listing process, lack of prior public market, and potential oversupply or lack of demand.
• Potential dilution from future issuances of preferred stock or additional common stock in connection with incentive plans, acquisitions, or otherwise.
• Lack of cash dividends on common stock, meaning shareholders may only receive a return on investment if they sell shares for a price greater than paid.
• Lack of research reports from securities industry analysts, or unfavorable reports, which could negatively affect market price and trading volume.
• Risk of common stock becoming subject to 'penny stock' rules, making it more difficult to trade shares.
• Ongoing public reporting requirements that are less rigorous for emerging growth companies and smaller reporting companies, potentially making common stock less attractive to some investors.

Future Outlook

The company anticipates continued operating losses and will require additional financing to support working capital needs and growth plans. Management believes meeting sales objectives is imperative to lessen reliance on external financing. The company aims to be a leader in the nutraceutical space by manufacturing high-quality products, strengthening the Kirkman brand, launching new brands like P2i, modernizing manufacturing, and investing heavily in sales, marketing, and business development, including potential partnerships or acquisitions. The direct listing on Nasdaq is expected to commence around November 4, 2025, but there is no assurance of approval.

Management Comments

• Management believes it is imperative that we meet these sales objectives in order to lessen our reliance on external financing in the future.
• We intend to continually monitor and adjust our operating plan as necessary to respond to developments in our business, our markets and the broader economy.
• We aim to be a leader in the nutraceutical space by manufacturing products held to the highest standard of quality in terms of toxins, metals, and other impurities.
• Our goal is to build a well-rounded portfolio of products including mushroom-based supplements targeted for everyday use, prenatal, athletes and beyond.

Industry Context

The company operates in the growing nutraceutical supplement and hemp-derived products industries. The global nutritional supplements market is projected to grow at a CAGR of 6.3% from 2023 to 2030, driven by increasing health awareness and prevalence of non-communicable diseases. The prenatal vitamin market is also experiencing significant growth (CAGR of 8.5%), supported by healthcare provider endorsements. The global CBD consumer health market is expanding rapidly (CAGR of 18.1%), influenced by positive government reforms and rising health awareness. Functional Brands aims to capitalize on these trends by focusing on high-quality products and expanding its brand portfolio, particularly with its certified P2i prenatal vitamin and diverse hemp offerings. However, the hemp industry faces unpredictable and evolving regulations, which could impact market growth and operational strategy.

Comparison to Industry Standards

• The Kirkman brand's 75+ year history and rigorous testing of every product batch for heavy metals and microbial contamination (exceeding FDA requirements for dietary supplements) positions it as a leader in purity and quality within the nutraceutical industry.
• The P2i by Kirkman prenatal vitamin is highlighted as the 'only certified prenatal vitamin in the market that aligns to the FIGO position statement,' setting a high standard for low-toxicity and safety compared to other prenatal supplements.
• In the multi-vitamin segment, market leaders include private label store brands, Nature Made, Centrum, One-A-Day, and Nature's Bounty. Kirkman operates in 95% of major subsegments, indicating broad market presence but facing strong competition from established players.
• Within the special needs category, Kirkman competes with companies like New Beginnings, Claire Labs, Houston Enzymes, and Lifetrients, which also focus on dietary sensitivities.
• In the hemp industry, competitors include Charlottes Web, cbdMD, Social CBD, Joy Organics, and MedTerra, many of which are larger and have greater financial resources. Functional Brands' exclusive license with Trailer Park Boys for Delta 9 products represents a niche strategy, though its revenue contribution is currently minimal (0.6%).

Management Changes

Corporate Governance

Legal Proceedings

• True Health Medical Center, S.C. has an ongoing lawsuit against Kirkman Group, Inc., HTO Nevada, Inc., and HTO Holdings, Inc. in Illinois, alleging underpayment of royalties from a terminated agreement.
• The lawsuit claims that HTO Parties, as purchasers of Kirkman assets, should be bound by the royalty agreement terms, despite never having paid royalties.
• There is no certain amount of damages claimed against the HTO Parties at this time, and the outcome of the proceeding is unpredictable.
• Discovery has been conducted, and True Health has filed a motion for summary judgment against Kirkman, but not against the HTO Parties; a ruling is expected in more than 60 days.
• Kirkman Group has filed a motion to amend its counterclaims against True Health, which could lead to additional discovery and further delay a trial date.

Related Party Transactions

• Eric Gripentrog, the Chief Executive Officer, has provided two loans to the company: $225,000 at an 18% annual interest rate (executed March 7, 2025, due March 7, 2029) and $130,000 at a 20% annual interest rate (executed March 11, 2024, due March 11, 2031).
• A short-term debt facility of $247,634 was entered into in December 2023 with an officer and director of the parent company, Hemptown Organics Corp. This loan was non-interest-bearing and reclassified to a general loan payable in January 2025 after the officer/director resigned.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from future equity issuances and the conversion of preferred stock. The direct listing process itself carries high volatility risks, and the 'going concern' doubt could lead to a partial or complete loss of investment. No cash dividends are anticipated in the foreseeable future.
• **Employees:** The company's ability to attract and retain highly qualified employees is crucial for success, and staff turnover could adversely affect efficiency. Executive officers have performance-based equity awards tied to company valuation and EBITDA, aligning their interests with growth.
• **Customers:** The company's reliance on a few key customers (iHerb, OceanSide Health) means that the loss of these relationships could significantly harm revenues. Product quality issues or recalls could tarnish brand image and reduce consumer trust.
• **Suppliers/Contractors:** The company relies on third-party suppliers for raw materials and hemp-derived products. Disruptions in the supply chain or significant price increases could impact operations and profitability. The termination of the Trailer Park Boys license agreement will affect a small portion of hemp-derived product revenue.
• **Creditors:** The company has substantial debt, including a $2.2 million payable for the Kirkman acquisition with a confession of judgment, which allows for foreclosure on assets in case of default. This poses a direct risk to creditors if the company cannot meet its obligations.

Next Steps

• Complete the direct listing on the Nasdaq Capital Market under the symbol MEHA, expected to begin trading on or about November 4, 2025.
• Cure the existing default of $2,227,366 owed for the Kirkman acquisition by November 15, 2025, using a portion of the private placement proceeds.
• Strengthen the existing Kirkman brand by curating product mix for the autism community.
• Launch multiple new brands, including P2i by Kirkman, to increase market share.
• Modernize manufacturing capabilities by reorganizing space and introducing new equipment.
• Invest heavily in sales and marketing activities and business development.
• Identify key companies with synergistic strengths for partnerships or acquisitions.
• Negotiate the termination of the license agreement with Trailer Park Boys Inc. by December 31, 2025, and pay remaining accrued royalties by March 31, 2026.
• Continue to monitor and assess the impact of evolving data privacy laws and regulations (e.g., CCPA, CPRA, GDPR).

Key Dates

Recommendation

The company's financial statements reveal a deeply concerning situation, with recurring net losses, negative cash flows, and a substantial accumulated deficit, leading auditors to express 'substantial doubt about its ability to continue as a going concern.' This fundamental instability is a critical red flag for any investor. While the direct listing aims to provide liquidity and raise capital, the company will not receive proceeds from the resale of shares by existing stockholders, and the private placement funding is contingent on the listing. The significant outstanding acquisition payable, coupled with multiple forbearance agreements and a confession of judgment, indicates severe liquidity pressures and a high risk of asset foreclosure. The novelty and inherent volatility of a direct listing, without the price stabilization mechanisms of a traditional IPO, further amplify investment risk. Given the severe financial challenges, operational uncertainties, and the explicit 'going concern' warning, a seasoned investor would likely recommend a 'strong sell' to avoid potential significant capital loss.

Keywords

Nutraceuticals, Supplements, Hemp Products, Direct Listing, Nasdaq, Kirkman, P2i Prenatal, CBD, CBG, Health Supplements, SEC Filing, S-1/A, Going Concern, Financial Performance, Risk Factors, Corporate Governance